Literature DB >> 10794714

Exon-skipping in BCR/ABL is induced by ABL exon 2.

B D Lichty1, S Kamel-Reid.   

Abstract

The BCR/ABL fusion gene is pathognomonic for chronic myelogenous leukaemia (CML). We have previously reported alternative splicing of BCR/ABL, as indicated by the detection of both p190- and p210-encoding transcripts, in about 60% of CML patient samples. These exon-skipping events involved the joining of ABL exon 2 to variable upstream BCR exons. Similarly, ABL exon 2 is alternatively spliced to either of two upstream ABL exons (1a or 1b) in c-ABL. We have constructed BCR and BCR/ABL minigenes to study this phenomenon in more detail. These constructs were transfected into various cell types and splicing was assessed by reverse transcriptase PCR. Whereas the basic BCR minigene expressed exon-inclusive transcripts only, insertion of genomic DNA spanning ABL exon 2 induced exon-skipping but only when expressed in the CML cell lines K562 and EM3. In this study we localized the required sequence element to ABL exon 2 itself. These results mimic the splicing phenotype displayed by most CML patients. We propose a model where a trans-factor present in some CML cells interacts with ABL exon 2 pre-mRNA to promote skipping of upstream BCR exons.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794714      PMCID: PMC1221036     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.

Authors:  M A van Dijk; A N Floore; K I Kloppenborg; L J van 't Veer
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  A complex intronic splicing enhancer from the c-src pre-mRNA activates inclusion of a heterologous exon.

Authors:  E F Modafferi; D L Black
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.

Authors:  A Castellanos; B Pintado; E Weruaga; R Arévalo; A López; A Orfao; I Sánchez-García
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

4.  Novel exonic elements that modulate splicing of the human fibronectin EDA exon.

Authors:  A Staffa; N H Acheson; A Cochrane
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

5.  A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?

Authors:  H Mittre; P Leymarie; M Macro; M Leporrier
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

6.  Detection of CBFbeta/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics.

Authors:  R Costello; D Sainty; P Lecine; A Cusenier; M J Mozziconacci; C Arnoulet; D Maraninchi; J A Gastaut; J Imbert; M Lafage-Pochitaloff; J Gabert
Journal:  Leukemia       Date:  1997-05       Impact factor: 11.528

7.  Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.

Authors:  J D Rowley
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

8.  The polypyrimidine tract binding protein binds upstream of neural cell-specific c-src exon N1 to repress the splicing of the intron downstream.

Authors:  R C Chan; D L Black
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

9.  Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer.

Authors:  R P Carstens; J V Eaton; H R Krigman; P J Walther; M A Garcia-Blanco
Journal:  Oncogene       Date:  1997-12-18       Impact factor: 9.867

10.  A splicing enhancer complex controls alternative splicing of doublesex pre-mRNA.

Authors:  M Tian; T Maniatis
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.